Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Joshua Phillips, a director at Sera Prognostics Inc. (NASDAQ:SERA), has sold shares worth approximately $230,468, according to a recent filing. The sale comes as the stock has experienced a significant 23% decline over the past week, according to InvestingPro data. The transactions, executed under a predetermined trading plan, involved the sale of Class A common stock at prices ranging from $6.29 to $8.03 per share. These sales, conducted over several days, were part of block trades and resulted in Phillips having no remaining shares held by Catalyst Health Ventures Follow-on Fund, L.P., among others. InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt and healthy liquidity ratios. For deeper insights into insider trading patterns and 8 additional key ProTips, consider accessing the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Sera Prognostics has announced significant developments. The Society for Maternal Fetal Medicine published an abstract containing top-line results from the PRIME study, a research project focused on improving neonatal outcomes through prematurity risk assessment and clinical interventions. The detailed findings of the study are expected to be presented later, followed by an in-depth discussion during a conference call and live webcast hosted by Sera Prognostics.
In relation to financials, Sera Prognostics reported a decrease in net revenue to $29,000 from $42,000, and an increase in operating expenses by 8% to $8.9 million, resulting in a 10% increase in net loss to $7.9 million. Despite these figures, the company maintains a strong cash reserve of $74.3 million, projected to fund operations into 2027.
The company has also emphasized the importance of its PreTRM test, with efforts to enhance its adoption in response to rising preterm birth rates in the U.S. These efforts have resulted in a 227% surge in website traffic, albeit with an 8% increase in operating expenses. The upcoming publication of the PRIME clinical study results is anticipated to play a crucial role in securing payer support and influencing clinical guidelines, forming a key part of Sera Prognostics' strategy for commercial growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.